Eagle Ridge Investment Management cut its holdings in shares of Atrion Co. (NASDAQ:ATRI) by 20.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 389 shares of the medical instruments supplier’s stock after selling 98 shares during the period. Eagle Ridge Investment Management’s holdings in Atrion were worth $332,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. BNP Paribas Arbitrage SA lifted its stake in Atrion by 4,866.7% during the first quarter. BNP Paribas Arbitrage SA now owns 298 shares of the medical instruments supplier’s stock worth $262,000 after purchasing an additional 292 shares during the last quarter. WINTON GROUP Ltd lifted its stake in Atrion by 131.9% during the second quarter. WINTON GROUP Ltd now owns 1,730 shares of the medical instruments supplier’s stock worth $1,475,000 after purchasing an additional 984 shares during the last quarter. Hudson Valley Investment Advisors Inc. ADV bought a new stake in Atrion during the second quarter worth $767,000. Pennsylvania Trust Co lifted its stake in Atrion by 441.3% during the first quarter. Pennsylvania Trust Co now owns 57,540 shares of the medical instruments supplier’s stock worth $9,082,000 after purchasing an additional 46,911 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its stake in Atrion by 27.8% during the fourth quarter. Principal Financial Group Inc. now owns 368 shares of the medical instruments supplier’s stock worth $273,000 after purchasing an additional 80 shares during the last quarter. Hedge funds and other institutional investors own 61.80% of the company’s stock.
Several brokerages have recently issued reports on ATRI. ValuEngine downgraded shares of Atrion from a “buy” rating to a “hold” rating in a report on Friday, July 26th. BidaskClub upgraded shares of Atrion from a “strong sell” rating to a “sell” rating in a report on Saturday, August 3rd.
Shares of NASDAQ:ATRI traded up $13.26 during trading on Thursday, hitting $735.30. 112 shares of the company were exchanged, compared to its average volume of 18,214. The stock has a 50 day simple moving average of $782.89. The firm has a market cap of $1.34 billion, a P/E ratio of 38.06 and a beta of 0.27. Atrion Co. has a 1-year low of $624.00 and a 1-year high of $948.03.
Atrion (NASDAQ:ATRI) last announced its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported $5.18 earnings per share (EPS) for the quarter. The company had revenue of $40.10 million during the quarter. Atrion had a net margin of 23.14% and a return on equity of 16.79%.
In other news, Director Ronald Nicholas Spaulding sold 170 shares of the company’s stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $903.00, for a total transaction of $153,510.00. Following the completion of the transaction, the director now directly owns 2,158 shares in the company, valued at $1,948,674. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 22.07% of the stock is currently owned by corporate insiders.
Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.
Further Reading: What is a Candlestick Chart?
Want to see what other hedge funds are holding ATRI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atrion Co. (NASDAQ:ATRI).
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.